Today's top medical abstracts
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Rheumatology
For Practicing
Rheumatologists
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Rheumatologists
Today's Rheumatology News: dnaJP1, A New Oral Treatment For RA
D Scott Cunningham MD, PhD, MDLinx Oncology
Today's Rheumatology News: FDA Approves Actemra
D Scott Cunningham MD, PhD, MDLinx Rheumatology
From the Editors: New Clinical-Only Option for MDLinx!
Stephen Smith, MDLinx
  See all
Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis
Journal of Rheumatology, 04/18/08
Print     Email This Article     Save in My Library   Free Abstract
Ringold S et al. - The presence of radiographic changes when the physician first suspected temporomandibular joint (TMJ) disease in 84% of JIA patients emphasizes the need for better screening and early intervention for synovitis in this joint.

Methods
  • Aim was to describe the clinical and radiographic outcomes in JIA pts who underwent one or more intraarticular corticosteroid (IAS) injections w/o imaging guidance
  • Retrospective chart review was performed for all JIA pts who underwent one or more IAS injections of their TMJ
  • IAS injections were performed by the same oral and maxillofacial surgeon w/o imaging guidance, using either triamcinolone acetonide or triamcinolone hexacetonide
  • The primary outcomes assessed were maximal incisal opening (MIO) measurements, patient-reported symptoms, physical examination findings, and imaging results

Results
  • 25 pts were identified
  • 84% had radiographic evidence of TMJ disease when TMJ disease was first suspected by their physician
  • The 25 pts underwent 74 IAS injections on 47 separate occasions
  • When baseline MIO measurements were compared to the last MIO measurements of the study period, there was a mean increase in MIO of 6.9 mm
  • There was a mean increase in MIO of 3.8 mm following each IAS injection
  • Pts who underwent multiple IAS injections had a mean increase in MIO after first injection of 6.6 mm
  • However, the mean increase in MIO after subsequent injections was 0.4 mm
  • 1 patient developed sc atrophy at the injection site
  • 2 pts developed small, asymptomatic intraarticular calcifications
  • No additional adverse events were reported

Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.